Clinical trial
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
NCT00348374
Study timeline
Study start (unknown)2006-06-01Date precision: month
Registry last updated2010-03-16
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Diabetes Mellitusunresolved
Interventions
Insulin LisproDRUG · verified · RxNorm: insulin lispro
ExuberaDRUG
Sponsors & collaborators
Pfizerlead sponsor
Mapped research locations
DallasTexas, United States2St LouisMissouri, United States2JacksonvilleFlorida, United States2HoustonTexas, United States1BostonMassachusetts, United States1ChicagoIllinois, United States1BaltimoreMaryland, United States1MiamiFlorida, United States1San AntonioTexas, United States1BirminghamAlabama, United States1San DiegoCalifornia, United States1Washington D.C.District of Columbia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00348374 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.